Related Experiment Videos
Cytolytic effector cells against human tumors: distinguishing phenotype and function
1Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Cancer Cells (Cold Spring Harbor, N.Y. : 1989)
|February 1, 1990
Summary
Tumor rejection mechanisms were studied using activated lymphocytes transferred to animal models. Key antitumor effector cells like natural killer cells and T cells were identified and characterized.
Area of Science:
- Immunology
- Cancer Research
Background:
- Lymphocyte activation and expansion in vitro are crucial for adoptive immunotherapy.
- Understanding effector cells involved in tumor rejection is vital for cancer treatment.
Purpose of the Study:
- To elucidate mechanisms of tumor rejection.
- To define the origins and properties of antitumor effector cells.
Main Methods:
- In vitro activation and expansion of lymphocytes.
- Adoptive transfer of lymphocytes to animal models.
- Phenotypic and functional characterization of effector cells.
Main Results:
- Several cell types exhibit antitumor activity, including natural killer (NK) cells, lymphokine-activated killer (LAK) cells, cytolytic T cells, and tumor-infiltrating lymphocytes (TILs).
- Distinct origins and properties differentiate these effector cells.
Conclusions:
- Activated lymphocytes are key in tumor rejection models.
- Characterizing NK cells, LAK cells, T cells, and TILs aids in developing effective cancer immunotherapies.